Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed?

Leukemia. 2017 Nov;31(11):2536-2537. doi: 10.1038/leu.2017.263. Epub 2017 Aug 18.

Authors

Y Zhou¹, B L Wood¹, R B Walter^{2

3}, P S Becker^{2

3}, M-E Percival^{2

3}, M Bar^{3

4}, C Shaw³, K Gardner², P Hendrie², J Abkowitz², F R Appelbaum^{3

4}, E Estey^{2

3}

Affiliations

¹ Division of Hematopathology, Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.
² Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA.
³ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
⁴ Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.

PMID: 28819284
DOI: 10.1038/leu.2017.263

No abstract available

MeSH terms

Flow Cytometry / methods
Granulocyte Precursor Cells / pathology
Humans
Immunophenotyping / methods
Leukemia, Myeloid, Acute / diagnosis*
Leukemia, Myeloid, Acute / pathology*
Neoplasm Recurrence, Local / pathology
Recurrence